Page last updated: 2024-08-24

gemcitabine and butyl isothiocyanate

gemcitabine has been researched along with butyl isothiocyanate in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Blaheta, RA; Chun, FK; Cinatl, J; Grein, T; Haferkamp, A; Khadir, SE; Makhatelashvili, N; Mann, J; Maxeiner, S; Rutz, J; Sonnenburg, M; Thomas, A; Tsaur, I; Xie, H	1

Other Studies

1 other study(ies) available for gemcitabine and butyl isothiocyanate

Article	Year
Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines. International journal of molecular sciences, 2022, Sep-20, Volume: 23, Issue:19 Topics: Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinases; Cyclins; Deoxycytidine; Gemcitabine; Humans; Isothiocyanates; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms	2022

Article

Year

Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.

International journal of molecular sciences, 2022, Sep-20, Volume: 23, Issue:19

Topics: Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinases; Cyclins; Deoxycytidine; Gemcitabine; Humans; Isothiocyanates; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms

2022